Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GEH 200520/GEH 200521

Next Previous
X
Search
Drug Profile

GEH 200520/GEH 200521

Alternative Names: 18F-CD8 PET; [18F]GEH200521; GEH-200520/GEH-200521; GEH200520 Injection /GEH200521 (18F) Injection

Latest Information Update: 07 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GE Healthcare
  • Class Diagnostic agents; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 03 May 2024 GE Healthcare plans a phase I trial pharmacokinetics trial (In volunteers, Diagnosis) (Parenteral, Injection) in May 2024 (NCT06398730)
  • 19 Jun 2023 Phase-I clinical trials in Solid tumours (Diagnosis) in Netherlands (Parenteral) (NCT05629689)
  • 01 Dec 2022 Preclinical trials in Solid tumours (Diagnosis) in United Kingdom (unspecified route, injection) before December 2022 (NCT05629689)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top